Cymipristone is a synthetic compound classified as a selective progesterone receptor modulator (SPRM). It is primarily researched for its potential applications in reproductive health, particularly in contraception and the treatment of conditions related to progesterone imbalance. Cymipristone exhibits a unique mechanism of action by selectively binding to progesterone receptors, which can lead to either agonistic or antagonistic effects depending on the target tissue. This selectivity allows for the modulation of progesterone activity, making it a candidate for therapeutic interventions in various gynecological disorders. The compound is characterized by its chemical structure, which includes specific functional groups that contribute to its biological activity. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile in clinical settings. Ongoing research aims to further elucidate its potential benefits and risks, as well as its overall role in hormonal therapies.

Cymipristone

329971-40-6: Cymipristone is a synthetic compound classified as a selective progesterone receptor modulator (SPRM). It is primarily researched for its potential applications in reproductive health, particularly in contraception and the treatment of conditions related to progesterone imbalance. Cymipristone exhibits a unique mechanism of action by selectively binding to progesterone receptors, which can lead to either agonistic or antagonistic effects depending on the target tissue. This selectivity allows for the modulation of progesterone activity, making it a candidate for therapeutic interventions in various gynecological disorders. The compound is characterized by its chemical structure, which includes specific functional groups that contribute to its biological activity. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile in clinical settings. Ongoing research aims to further elucidate its potential benefits and risks, as well as its overall role in hormonal therapies.

Cymipristone, a progesterone receptor antagonist, is used potentially for termination of intrauterine pregnancy.

CAS 329971-40-6

Cymipristone

Cymipristone

Ref: TM-T27108